Advancing In-Vivo & Solid Tumour Cell Therapies Through Scalable Manufacturing & Clinical Excellence to Progress Cost-Effective Trials & Unlock Critical Investment
Cell therapy is entering one of its most consequential chapters yet. As the industry pivots toward in vivo approaches, ex vivo solid tumour programmes regain momentum and investment becomes increasingly selective; developers must make critical decisions about where to invest their time, how to differentiate their asset and position their programmes for long-term success.
Bringing together leaders from biotech, pharma, academia and investment, the 10th CAR-TCR Summit Europe delivers the technical depth, candid discussion and strategic perspective needed to navigate a rapidly evolving landscape and accelerate progress through the clinic.
From deep scientific debate to emerging investment, scaling and partnering strategies, this is where the cell therapy community comes to benchmark progress, challenge assumptions and understand what's shaping the future of the field.
2027 Speaker Faculty
Companies Attending Include